Icahn slams Forest for undisclosed FDA warning

On the eve of Forest Laboratories' proxy vote, activist investor Carl Icahn is still campaigning. After accusing Forest's board of cronyism and lethargy, after critiquing CEO Howard Solomon's performance--and his son's résumé--Icahn is taking the company to task for a recent FDA warning letter. Not only was the letter itself worrisome, Icahn said, but Forest didn't disclose it in a recent quarterly filing with the Securities and Exchange Commission. Story

Like what you're reading?
Click here to get more news like this delivered to your inbox everyday>>

Suggested Articles

Illustration of three DNA helices
Biotech

Solid Bio clears partial hold, but DMD trial is still on hold

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

by Amirah Al Idrus
fda
Biotech

FDA seeks more cash to streamline drug development

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

by Nick Paul Taylor
Cannabis
Biotech

GW Pharma riding high as Epidiolex nears first U.S. approval

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.

by Amirah Al Idrus